Глобальный рынок лечения синдрома Барта – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка лечения синдрома Барта

У большинства мужчин, страдающих синдромом Барта, наблюдается нейтропения. У мужчин с синдромом Барта в крови и моче повышен уровень вещества, называемого 3-метилглутаконовой кислотой. Предполагается, что синдром Барта поразит примерно 1 из 300 000–400 000 человек во всем мире. На сегодняшний день описано более 150 случаев.  

Data Bridge Market Research анализирует темпы роста рынка лечения синдрома Барта в прогнозируемый период 2023-2030 гг. Ожидаемый среднегодовой темп роста рынка лечения синдрома Барта, как правило, составляет около 13% в указанный прогнозируемый период. Рынок был оценен в 126,01 млрд долларов США в 2022 году, и он вырастет до 335 млрд долларов США к 2030 году. В дополнение к рыночным данным, таким как рыночная стоимость, темпы роста, сегменты рынка, географический охват, участники рынка и рыночный сценарий, рыночный отчет, подготовленный командой Data Bridge Market Research, также включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Масштаб и сегментация рынка лечения синдрома Барта

Market Definition

Barth syndrome is a rare type of genetic lipid metabolism disorder that primarily affects the males. It happens because of mutation in a TAZ gene that declines the enzyme production of cardiolipin. Symptoms include weakness, less mobility of muscles and others. In males suffering from Barth syndrome, dilated cardiomyopathy often exist at birth or develops within the first months of life  

Barth Syndrome Treatment Market Dynamics

Drivers

• Growing Prevalence Of Barth Syndrome

Barth syndrome affects almost all ethnic groups. The prevalence of barth syndrome is projected to be around 1 in 300,000 to 1 in 400,00 in U.S. As of 2013, there have been around 151 patients reported.  Thus, this increasing prevalence boosts the market growth.

• Increased Diagnosis of Barth Syndrome

Barth syndrome is generally diagnosed during infancy or early childhood, but has been diagnosed later in many patients. Multiple pregnancy losses which involves a male fetus have been witnessed in some families with barth syndrome. Molecular genetic testing for mutations in the TAZ gene checks the diagnosis of barth syndrome. The TAZ gene testing can be done either individually or as a part of a multigene panel. Thus, these varied diagnostic methods are boosting the faster treatment processes.

Opportunities

• Growing Treatment Methods

Many standard heart failure medications have been used, such as beta blockers, ACE inhibitors and digoxin. This helps in improving the heart function and decreases symptoms of heart failure. Furthermore, aspirin is used for decreasing clot formation. Heart transplant is also considered when there is extreme heart failure. The heart functioning tends to improve post infancy, so heart transplant should be carefully considered. Genetic counseling is also recommended for affected individuals and their families. Other treatment for this disorder is symptomatic and much supportive. Thus, all these treatment methods are boosting the growth of the market.

Restraints/Challenges

• High Cost of Treatment

The huge expenditure required for the surgeries and treatment processes impedes market growth. Several market players make several huge investments in manufacturing new and advanced treatment procedures to fasten the recovery process, and in return, the cost is increased.

This barth syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the barth syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Barth Syndrome Treatment Market Scope

The barth syndrome treatment market is segmented on the basis of application, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Dilated Cardiomyopathy
• Skeletal Myopathy
• Neutropenia
• Others

Treatment

• Antibiotics
• Granulocyte Colony Stimulating Factor (GCSF)

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Barth Syndrome Treatment Regional Analysis/Insights

The barth syndrome treatment market is analyzed and market size insights and trends are provided by application, treatment, distribution channel and end-user as referenced above.

The major countries covered in the barth syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period due to the increasing prevalence of neurological disorders and mounting technological advancements.

Asia-Pacific is considered to grow over the coming years because of the increasing public awareness and increasing healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Анализ конкурентной среды и доли мирового лечения синдрома Барта

Конкурентная среда рынка лечения синдрома Барта содержит данные по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, глобальное присутствие, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта, доминирование приложений. Приведенные выше данные относятся только к фокусу компаний, связанному с рынком лечения синдрома Барта

Ключевые игроки, работающие на рынке лечения синдрома Барта:

• Amneal Pharmaceuticals LLC. (США)
• Boehringer Ingelheim International GmbH. (Германия)
• Merck & Co Inc. (США)
• Эбботт (США)
• B Braun SE (Германия)
• Integra LifeSciences (США)
• Johnson & Johnson Services, Inc. (Индия)
• Medtronic (Ирландия)
• MicroPort Scientific Corporation (Китай)
• NuVasive, Inc(США)
• Orthofix US LLC (США)
• Компания Перриго, ООО. (Ирландия)
• Корпорация Stryker (США)
• Zimmer Biomet (США)
• Лилли (США)
• F. Hoffmann-La Roche Ltd. (Швейцария)
• Mylan NV (США)

SKU-60713